Browse News
Filter News
Found 28 articles
-
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
2/9/2023
AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2022.
-
Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
-
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
1/10/2023
AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology.
-
Dexcom Appoints Teri Lawver as Chief Commercial Officer
1/9/2023
DexCom, Inc. announced today the appointment of Teri Lawver to the newly created role of chief commercial officer.
-
With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem. Venture capitalists would do well to pay attention.
-
Healthcare Bioconvergence Market Size, Share, Growth, Report 2022-2030
8/25/2022
Latest Research Study on “Healthcare Bioconvergence Market (By Application: Drug Discovery, Nanorobotics for Drug Delivery, Regenerative Medicine, Diagnostic and Biological Sensors, Bioelectronics, Engineered Living Materials, Optogenetics, Precision Medicine)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030”.
-
Biopharma Executive Perspectives on 2022
1/10/2022
BioSpace sat down with 12 executives who shared their thoughts on the coming year and decade. -
mRNA has built its reputation as a type of vaccine to fight COVID-19, but its capabilities extend beyond vaccines into therapeutics and even diagnostics.
-
“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima Biotech. That isn’t merely his opinion. The question arises in partnering meetings routinely.
-
Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
4/12/2021
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the hiring of Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan
-
Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
3/9/2021
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5% reduction in seizure frequency for ganaxolone compared to 24.0% for placebo (p=0.17)
-
Biopharma Executive Perspectives on 2021
1/11/2021
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay. -
Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
10/23/2019
Revenue in the third quarter of 2019 grew 3 percent, driven by 8 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, contributed 12 percentage points of revenue growth and represented approximately 44 percent of total revenue.
-
Wouldn’t it be amazing to be able to see a protein being made in a cell in real time? And wouldn’t it be even better if you could use that capability to discover new drugs to previously “undruggable” targets, creating new medicines? Well that’s exactly what Anima Biotech is aiming to do.
-
Anima Biotech is merging mRNA therapeutics with its own AI and bioinformatics capability. Yochi Slonim, co-founder and chief executive officer of Anima Biotech, took time to speak with BioSpace about the company and mRNA therapeutics.
-
Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance
11/6/2018
Third-quarter 2018 revenue increased 7 percent, driven primarily by increased demand for new medicines, while operating expenses increased 1 percent.
-
Anima Biotech, based in Bernardsville, New Jersey, inked a discovery and development deal with Eli Lilly and Co. that has the potential to exceed $1 billion.
-
Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets
7/23/2018
Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors.
-
One of the growing areas in the medical device industry is new approaches to drug delivery. Here are the top 5 drug delivery companies that you must be aware of.